(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
• 化学式: C54H66F6N4O6
• 分子量: 981.1
• InChiKey: LPAQAJIKFZOWNF-DXHGTRDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.8
• 重原子数：
  70
• 可旋转键数：
  12
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  137
• 氢给体数：
  4
• 氢受体数：
  13

文献信息

• PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF
  申请人：Aciex Therapeutics, Inc.

  公开号：EP2847207A1

  公开（公告）日：2015-03-18
• [EN] PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF<br/>[FR] PRÉPARATIONS D'AGENTS THÉRAPEUTIQUES HYDROPHOBES, PROCÉDÉS DE FABRICATION ET UTILISATION DE CEUX-CI
  申请人：ACIEX THERAPEUTICS INC

  公开号：WO2013169647A1

  公开（公告）日：2013-11-14

  The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
• [EN] PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF<br/>[FR] PRÉPARATIONS D'AGENTS THÉRAPEUTIQUES HYDROPHOBES, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：ACIEX THERAPEUTICS INC

  公开号：WO2014107231A1

  公开（公告）日：2014-07-10

  The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).